Skip to main content

Table 3 Incidence of adverse events reported in the artesunate-amodiaquine treatment arm according to CYP2C8 genotype

From: Influence of cytochrome P450 (CYP) 2C8 polymorphisms on the efficacy and tolerability of artesunate‐amodiaquine treatment of uncomplicated Plasmodium falciparum malaria in Zanzibar

  *1/*1 *2 carriers *3 carriers
Adverse events; % (n) 28.1 (55) 45.9 (50) 38.9 (7)
No adverse events; % (n) 71.9 (141) 54.1 (59) 61.1 (11)
Total; % (n) 100 (196) 100 (109) 100 (18)
  1. Out of the 329 subjects analysed for CYP2C8, 6 had incomplete data regarding adverse events and were therefore excluded from these calculations
\